BC Extra | Dec 26, 2019
Clinical News

Spectrum’s value halved after poziotinib’s failure in NSCLC cohort

Eleven months after Spectrum divested its marketed products to sharpen its focus on a pair of clinical candidates, one of the two has failed in the first cohort of a Phase II trial, while the...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Extra | Mar 15, 2019
Company News

Another setback for Spectrum's remaining pipeline after Rolontis BLA withdrawal

Spectrum said Friday that it withdrew a BLA for Rolontis eflapegrastim to treat chemotherapy-induced neutropenia. Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said it needs more time to provide additional manufacturing-related information to FDA, which was due before...
BC Week In Review | Jan 18, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Extra | Jan 17, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BioCentury | Jan 12, 2019
Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BC Week In Review | Dec 21, 2018
Clinical News

No breakthrough therapy designation for Spectrum's poziotinib

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) lost $4.05 (39%) to $6.39 on Dec. 20 after announcing after market close on Dec. 19 that based on data from an investigator-sponsored Phase II trial FDA did not grant breakthrough...
BC Extra | Oct 19, 2018
Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
BC Week In Review | Jul 6, 2018
Clinical News

Spectrum's Rolontis meets in second Phase III for chemotherapy-induced neutropenia

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said Rolontis eflapegrastim met the primary endpoint of non-inferiority to Neulasta pegfilgrastim in the Phase III RECOVER trial in 237 early stage breast cancer patients who received docetaxel and cyclophosphamide every...
BC Innovations | Jun 28, 2018
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived metastatic neuroendocrine prostate cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by culturing enzyme-dissociated cells from samples of a patient’s liver, lymph node...
Items per page:
1 - 10 of 588
BC Extra | Dec 26, 2019
Clinical News

Spectrum’s value halved after poziotinib’s failure in NSCLC cohort

Eleven months after Spectrum divested its marketed products to sharpen its focus on a pair of clinical candidates, one of the two has failed in the first cohort of a Phase II trial, while the...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Extra | Mar 15, 2019
Company News

Another setback for Spectrum's remaining pipeline after Rolontis BLA withdrawal

Spectrum said Friday that it withdrew a BLA for Rolontis eflapegrastim to treat chemotherapy-induced neutropenia. Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said it needs more time to provide additional manufacturing-related information to FDA, which was due before...
BC Week In Review | Jan 18, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Extra | Jan 17, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BioCentury | Jan 12, 2019
Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BC Week In Review | Dec 21, 2018
Clinical News

No breakthrough therapy designation for Spectrum's poziotinib

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) lost $4.05 (39%) to $6.39 on Dec. 20 after announcing after market close on Dec. 19 that based on data from an investigator-sponsored Phase II trial FDA did not grant breakthrough...
BC Extra | Oct 19, 2018
Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
BC Week In Review | Jul 6, 2018
Clinical News

Spectrum's Rolontis meets in second Phase III for chemotherapy-induced neutropenia

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said Rolontis eflapegrastim met the primary endpoint of non-inferiority to Neulasta pegfilgrastim in the Phase III RECOVER trial in 237 early stage breast cancer patients who received docetaxel and cyclophosphamide every...
BC Innovations | Jun 28, 2018
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived metastatic neuroendocrine prostate cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by culturing enzyme-dissociated cells from samples of a patient’s liver, lymph node...
Items per page:
1 - 10 of 588